Precision appoints John Hubbard, PhD, as Board of Directors Chair
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
Marksans' OTC Famotidine Tablets USP are acid reducers
The agreement is for USFDA approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets
Resomer used in commercial 3D-printed implants for both soft and hard tissue applications
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
Subscribe To Our Newsletter & Stay Updated